Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2069]

Novel targets and immune based therapy in myeloma

Dr Kenneth Anderson; Prof Antonio Palumbo; Prof Gareth Morgan; Prof Jesús San...

Novel targets and immune based therapy in myeloma ( Dr Kenneth Anderson; Prof Antonio Palumbo; Prof Gareth Morgan; Prof Jesús San Miguel )

Recent advances in mantle cell lymphoma: Expert panel discussion

Prof Simon Rule; Prof Umberto Vitolo; Prof Pier Luigi Zinzani; Prof Emanuele...

Recent advances in mantle cell lymphoma: Expert panel discussion ( Prof Simon Rule; Prof Umberto Vitolo; Prof Pier Luigi Zinzani; Prof Emanuele Zucci )

Lecture: Current standard of care in advanced disease

Dr Wayne YH Chang - National Yang-Ming University Taipei, Taiwan

Lecture: Current standard of care in advanced disease ( Dr Wayne YH Chang - National Yang-Ming University Taipei, Taiwan )

Lecture: Exploring the androgen signalling pathway in CRPC

Dr Paul de Souza - University of Western Sydney, New South Wales, Australia

Lecture: Exploring the androgen signalling pathway in CRPC ( Dr Paul de Souza - University of Western Sydney, New South Wales, Australia )

Lecture: Clinical perspectives: Non-AR therapeutic targets in CRPC

Dr Kurt Miller - Benjamin Franklin Medical Center, Berlin, Germany;

Lecture: Clinical perspectives: Non-AR therapeutic targets in CRPC ( Dr Kurt Miller - Benjamin Franklin Medical Center, Berlin, Germany; )

Debate: Will chemotherapy continue to be standard treatment for symptomatic...

Dr Paul de Souza - University of Western Sydney, New South Wales, Australia

Debate: Will chemotherapy continue to be standard treatment for symptomatic mCRPC in the era of novel agents? (for) ( Dr Paul de Souza - University of Western Sydney, New South Wales, Australia )

Lecture: Clinical Perspectives: How far are we from personalising treatment for...

Dr Paul de Souza - University of Western Sydney, New South Wales, Australia

Lecture: Clinical Perspectives: How far are we from personalising treatment for prostate cancer patients? ( Dr Paul de Souza - University of Western Sydney, New South Wales, Australia )

Debate: Will chemotherapy continue to be standard treatment for symptomatic...

Dr Kurt Miller - Benjamin Franklin Medical Center, Berlin, Germany

Debate: Will chemotherapy continue to be standard treatment for symptomatic mCRPC in the era of novel agents? (against) ( Dr Kurt Miller - Benjamin Franklin Medical Center, Berlin, Germany )

Lecture: Future strategies and targets for prostate cancer

Dr Kurt Miller - Benjamin Franklin Medical Center Berlin, Germany

Lecture: Future strategies and targets for prostate cancer ( Dr Kurt Miller - Benjamin Franklin Medical Center Berlin, Germany )

Rituximab versus idelalisib in refractory CLL

Prof John Gribben - Queen Mary University London, London, UK; Prof Peter...

$Rituximab versus idelalisib in refractory CLL ( Prof John Gribben - Queen Mary University London, London, UK; Prof Peter Hillmen - St James’ University Hospital, Leeds, UK )$

Use of GA101 and Clb preferable to rituximab in elderly or unfit chronic...

Dr Valentin Goede - University of Cologne, Cologne, Germany

Use of GA101 and Clb preferable to rituximab in elderly or unfit chronic lymphocytic leukaemia patients ( Dr Valentin Goede - University of Cologne, Cologne, Germany )

WIN Symposium 2014: Breakthrough biomarker investigations and combination...

Dr John Mendelsohn, Dr Razelle Kurzrock, Dr Mace Rothenberg

WIN Symposium 2014: Breakthrough biomarker investigations and combination therapies ( Dr John Mendelsohn, Dr Razelle Kurzrock, Dr Mace Rothenberg )

More from ecancer